S&P 500   3,310.24 (-0.46%)
DOW   29,079.46 (-0.28%)
QQQ   224.19 (-0.18%)
AAPL   322.23 (+0.94%)
FB   219.45 (-0.14%)
MSFT   166.83 (+0.07%)
GOOGL   1,480.49 (-0.28%)
AMZN   1,876.39 (-0.43%)
NVDA   254.57 (+0.68%)
BABA   216.78 (-1.07%)
MU   58.81 (-0.68%)
TSLA   564.83 (-1.29%)
AMD   51.01 (-1.35%)
T   38.63 (-0.03%)
NFLX   351.55 (+0.56%)
BAC   33.59 (-1.55%)
DIS   140.39 (-1.27%)
GILD   63.37 (-0.89%)
S&P 500   3,310.24 (-0.46%)
DOW   29,079.46 (-0.28%)
QQQ   224.19 (-0.18%)
AAPL   322.23 (+0.94%)
FB   219.45 (-0.14%)
MSFT   166.83 (+0.07%)
GOOGL   1,480.49 (-0.28%)
AMZN   1,876.39 (-0.43%)
NVDA   254.57 (+0.68%)
BABA   216.78 (-1.07%)
MU   58.81 (-0.68%)
TSLA   564.83 (-1.29%)
AMD   51.01 (-1.35%)
T   38.63 (-0.03%)
NFLX   351.55 (+0.56%)
BAC   33.59 (-1.55%)
DIS   140.39 (-1.27%)
GILD   63.37 (-0.89%)
S&P 500   3,310.24 (-0.46%)
DOW   29,079.46 (-0.28%)
QQQ   224.19 (-0.18%)
AAPL   322.23 (+0.94%)
FB   219.45 (-0.14%)
MSFT   166.83 (+0.07%)
GOOGL   1,480.49 (-0.28%)
AMZN   1,876.39 (-0.43%)
NVDA   254.57 (+0.68%)
BABA   216.78 (-1.07%)
MU   58.81 (-0.68%)
TSLA   564.83 (-1.29%)
AMD   51.01 (-1.35%)
T   38.63 (-0.03%)
NFLX   351.55 (+0.56%)
BAC   33.59 (-1.55%)
DIS   140.39 (-1.27%)
GILD   63.37 (-0.89%)
S&P 500   3,310.24 (-0.46%)
DOW   29,079.46 (-0.28%)
QQQ   224.19 (-0.18%)
AAPL   322.23 (+0.94%)
FB   219.45 (-0.14%)
MSFT   166.83 (+0.07%)
GOOGL   1,480.49 (-0.28%)
AMZN   1,876.39 (-0.43%)
NVDA   254.57 (+0.68%)
BABA   216.78 (-1.07%)
MU   58.81 (-0.68%)
TSLA   564.83 (-1.29%)
AMD   51.01 (-1.35%)
T   38.63 (-0.03%)
NFLX   351.55 (+0.56%)
BAC   33.59 (-1.55%)
DIS   140.39 (-1.27%)
GILD   63.37 (-0.89%)
Log in

CVE:BTI - biOasis Technologies Stock Price, Forecast & News

C$0.21
0.00 (0.00 %)
(As of 01/24/2020 11:57 AM ET)
Today's Range
C$0.21
Now: C$0.21
C$0.22
50-Day Range
C$0.19
MA: C$0.21
C$0.27
52-Week Range
C$0.18
Now: C$0.21
C$0.55
Volume10,000 shs
Average Volume41,760 shs
Market CapitalizationC$13.27 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company's lead program is xB3-001, an xB3 peptide vector-trastuzumab fusion. It is developing xB3, a proprietary platform technology for the delivery of therapeutics and imaging agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders in the areas of high unmet medical needs, including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain metastases, glioblastomas, and neurodegenerative diseases. Bioasis Technologies Inc. has a collaborative research agreement with CQDM and Brain Canada to perform research on the delivery of therapeutic compounds across the BBB; and a strategic collaboration with BIOAGILYTIX for the development and validation of bioanalytical methods to support the xB3 TM-001 program, as well with WuXi Biologics (Hong Kong) Limited for the development and manufacturing of xB3-001 to treat cancer. The company was incorporated in 2006 and is headquartered in Guilford, Connecticut.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-604-2957014

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$1.76 million
Cash FlowC$0.01 per share
Book ValueC($0.03) per share

Profitability

Miscellaneous

EmployeesN/A
Market CapC$13.27 million
Next Earnings Date2/4/2020 (Estimated)
OptionableOptionable

Receive BTI News and Ratings via Email

Sign-up to receive the latest news and ratings for BTI and its competitors with MarketBeat's FREE daily newsletter.


biOasis Technologies (CVE:BTI) Frequently Asked Questions

What is biOasis Technologies' stock symbol?

biOasis Technologies trades on the Canadian Venture Exchange (CVE) under the ticker symbol "BTI."

When is biOasis Technologies' next earnings date?

biOasis Technologies is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for biOasis Technologies.

Has biOasis Technologies been receiving favorable news coverage?

News stories about BTI stock have been trending somewhat negative this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. biOasis Technologies earned a coverage optimism score of -1.9 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for biOasis Technologies.

Who are some of biOasis Technologies' key competitors?

What other stocks do shareholders of biOasis Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other biOasis Technologies investors own include Extendicare (EXE), General Cannabis (CANN), Praxair (PX), Blackstone Mortgage Trust (BXMT), Bank of America (BAC), Morningstar (MORN), Five Below (FIVE) and OrganiGram (OGI).

Who are biOasis Technologies' key executives?

biOasis Technologies' management team includes the folowing people:
  • Dr. Deborah Ann Rathjen B.Sc. (Hons.), Q.C., Ph.D., M.A.I.C.D., FTSE, Exec. Chair, CEO & Pres (Age 61)
  • Ms. Christine Antalik, Chief Financial Officer (Age 48)
  • Mr. Graeme Dick, Director of Investor Relations
  • Mr. Kim Elton, Director of Marketing
  • Mr. Doug Williams MBA, Exec. VP & Chief Bus. Officer

How do I buy shares of biOasis Technologies?

Shares of BTI and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is biOasis Technologies' stock price today?

One share of BTI stock can currently be purchased for approximately C$0.21.

How big of a company is biOasis Technologies?

biOasis Technologies has a market capitalization of C$13.27 million and generates C$1.76 million in revenue each year. View Additional Information About biOasis Technologies.

What is biOasis Technologies' official website?

The official website for biOasis Technologies is http://www.bioasis.ca/.

How can I contact biOasis Technologies?

biOasis Technologies' mailing address is 130-10691 Shellbridge Way, RICHMOND, BC V6X 2W8, Canada. The company can be reached via phone at +1-604-2957014.


MarketBeat Community Rating for biOasis Technologies (CVE BTI)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  53 (Vote Outperform)
Underperform Votes:  43 (Vote Underperform)
Total Votes:  96
MarketBeat's community ratings are surveys of what our community members think about biOasis Technologies and other stocks. Vote "Outperform" if you believe BTI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BTI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel